Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema
- 28 January 2015
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 99 (7), 960-966
- https://doi.org/10.1136/bjophthalmol-2014-306366
Abstract
Purpose To determine whether vitreal concentrations of MCP-1, IL-6 and IL-8 are altered after vitrectomy in patients with proliferative diabetic retinopathy (PDR) and to investigate whether the altered levels of these cytokines are associated with postoperative macular oedema. Methods Vitreous samples were collected from 36 eyes of 33 patients with PDR before pars plana vitrectomy without intraocular lens (IOL) implantation, and also from the same 36 eyes during IOL implantation surgery approximately 7 months after the initial vitrectomy. Levels of MCP-1, IL-6, IL-8 and vascular endothelial growth factor were measured by flow cytometry using cytometric bead array (CBA) technology. Results The mean vitreous levels of MCP-1, IL-6 and IL-8 in the samples collected before vitrectomy were significantly higher in patients with PDR than in control patients (pConclusions The elevated levels of MCP-1 and IL-6 may indicate prolonged inflammation even after successful vitrectomy, which can cause postoperative DME.Keywords
This publication has 25 references indexed in Scilit:
- Inflammation and Pharmacological Treatment in Diabetic RetinopathyMediators of Inflammation, 2013
- Soluble Mediators of Diabetic Macular Edema: The Diagnostic Role of Aqueous VEGF and Cytokine Levels in Diabetic Macular EdemaCurrent Diabetes Reports, 2013
- Antiangiogenic Shift in Vitreous after Vitrectomy in Patients with Proliferative Diabetic RetinopathyInvestigative Opthalmology & Visual Science, 2012
- Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide PerspectiveSurvey of Ophthalmology, 2012
- Reduced concentrations of angiogenesis-related factors in vitreous after vitrectomy in patients with proliferative diabetic retinopathyAlbrecht von Graefes Archiv für Ophthalmologie, 2010
- Comprehensive Analysis of Inflammatory Immune Mediators in Vitreoretinal DiseasesPLOS ONE, 2009
- Association of Vitreous Inflammatory Factors with Diabetic Macular EdemaOphthalmology, 2009
- Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized EyesAmerican Journal of Ophthalmology, 2007
- Challenges in ophthalmic pathology: The vitreoretinal membrane biopsyEye, 2000
- Long-term Diabetic Vitrectomy ResultsOphthalmology, 1985